The Radoff‑JEC Group, which holds roughly 7.6 % of Seer, Inc.’s outstanding shares, filed a non‑binding proposal on April 13 2026 to acquire the company for $2.25 per share in cash. The offer represents a 33 % premium to Seer’s most recent closing price of $1.69 and includes a contingent value right that would entitle shareholders to 80 % of the net proceeds from any future sale or disposition of Seer’s business and assets, including its PrognomiQ unit.
The proposal is backed by an estimated $215 million in net cash and cash equivalents at closing and is expected to close by April 30 2026. No financing conditions are attached, and the Radoff‑JEC Group has indicated it will provide the necessary liquidity to complete the transaction.
Three director candidates—Howard H. Berman, Joshua S. Horowitz and Luis E. Rinaldini—have been nominated for election at Seer’s 2026 annual meeting, signaling the group’s intent to influence the company’s governance if the proposal is accepted.
Seer’s share price has fallen 97 % to $1.69, and the company has reported modest revenue growth. Q4 2025 revenue reached $16.6 million, a 17 % year‑over‑year increase from $14.2 million in 2024, while full‑year 2025 revenue also stood at $16.6 million. Management has guided 2026 revenue to $16 million–$18 million, a roughly 3 % increase from the prior year. The company’s cash balance is $240.6 million with no debt, but it has posted net losses and is projected to burn $40 million in cash in 2026. Gross margins improved to 52 % in Q4 2025 from 51 % in the full year, up from 50 % in 2024.
CEO Omid Farokhzad said in the Q4 2025 earnings release that “2025 was a challenging year as our customers navigated ongoing budgetary pressures, including uncertainty around NIH funding in the fourth quarter. Despite this persistently challenging funding environment, we made meaningful progress across our business. Our installed base grew significantly, consumable kit volume increased, the number of publications expanded throughout the year, and the Proteograph was selected to power multiple population‑scale studies. I am more confident than ever in our opportunities in 2026 and beyond.”
The Radoff‑JEC Group previously disclosed a 6.5 % stake in February 2026 and has engaged with Seer’s board, criticizing the company’s leadership and operational results. The group highlighted the projected $40 million cash burn in 2026 as unsustainable, prompting the current takeover proposal.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.